Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 18 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Alpelisib and Olaparib for treating platinum-resistant or refractory BRCA wild-type ovarian cancer	Alpelisib (BYL719; Piqray) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Ovarian cancer	Female Reproductive Cancer	2022	View \| Download
Cediranib in combination with olaparib for recurrent platinum-resistant ovarian cancer – fourth line or greater	Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Cediranib with olaparib for previously treated platinum resistant recurrent ovarian cancer	Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Ovarian cancer	Female Reproductive Cancer	2021	View \| Download
Durvalumab with carboplatin and paclitaxel with or without olaparib for newly diagnosed advanced or reccurent endometrial cancer	Carboplatin (Paraplatin) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Paclitaxel (Taxol; paclitaxel albumin)	Endometrial cancer	Female Reproductive Cancer	2023	View \| Download
Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2017	View \| Download
Olaparib for BRCA mutated and high risk HER2 negative breast cancer - adjuvant therapy	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Breast cancer	Breast Cancer	2020	View \| Download
Olaparib for BRCAm or ATM mutated metastatic castration-resistant prostate cancer	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Olaparib for Metastatic Pancreatic Cancer with gBRCA Mutation	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Pancreatic cancer	Gastrointestinal Cancer	2018	View \| Download
Olaparib in addition to abiraterone for metastatic castration-resistant prostate cancer – First line	Abiraterone acetate (Zytiga; Yonsa) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Olaparib in combination with bevacizumab for ovarian, fallopian tube or primary peritoneal cancer – maintenance therapy	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Fallopian tube cancer , Ovarian cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download